Translational relevance
Met is one of the most promising new therapeutic targets in lung cancer. An important activating mechanism is met amplification. There are, however, conflicting data on the prevalence of met amplification and the criteria for measurement of met changes in pulmonary carcinomas. Therefore, in situ hybridization has not yet been fully evaluated as a potential biomarker. In this work we describe our met FISH findings on a cohort of nearly 700 well characterized therapy-naïve lung cancers.
Based on this to date largest series, we describe prevalence and patterns of met amplification and propose clear-cut evaluation criteria. Furthermore, we provide evidence that met amplification occurs in adeno-and squamous cell carcinomas at the same frequency and can be found even in EGFR and KRAS mutated tumors.
These findings are relevant for the treatment of lung cancer with both EGFR and met inhibitors. 
INTRODUCTION
Lung cancer is the leading cause of cancer-related deaths in the Western world, and an estimated number of 230,000 newly diagnosed cases will occur in the year 2013 in the US with approximately 160,000 deaths (1). Better understanding of the molecular pathophysiology of non-small cell lung cancer (NSCLC) has led to the development of more selective and targeted treatment options with improved outcome rates (2, 3) . With the discovery of Epidermal growth factor receptor (EGFR) mutations, EML4-ALK (Echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase) translocations and the ROS1 translocation, lung cancer treatment has been fundamentally changed and shown to be much more effective than ancient chemo-radiation therapy regimens (4-7).
More recently, the MET receptor tyrosine kinase and its ligand the hepatocyte growth factor (HGF), also known as scatter factor (SF), were identified as further therapeutically relevant targets in lung cancer (3) . MET is a heterodimeric transmembrane receptor tyrosine kinase, composed of an extracellular α-chain and a transmembrane spanning β-chain linked via disulfide bonds (2) and its gene is MET signaling is maintained throughout adult life where it plays an important physiologic role for cell migration, cell growth, cell differentiation, angiogenesis and cell survival (11) . Dysregulation of the MET-HGF signaling pathway has been Author Manuscript Published OnlineFirst on December 9, 2014; DOI: 10.1158/1078-0432.CCR- reported in many different cancer types (3) and results in cancer cell proliferation, survival, invasion, motility and the formation of metastasis (12) (13) (14) . MET overexpression was shown in various cancer tissues and correlated with disease progression (15) (16) (17) . However, MET expression in non-small cell lung cancer is reported controversially and ranges from 5%-75% with most of the studies indicating a negative prognostic impact (18) .
Disturbed MET expression can occur by multiple mechanisms, including overexpression, kinase activation, paracrine and autocrine activation via HGF, MET mutation, epigenetic changes as well as MET gene amplification (2, (19) (20) (21) (22) . In NSCLC patients, amplification of the MET gene was shown to correlate with poor clinical prognosis (2) and increased MET gene copy numbers in general were shown to be an independent prognostic factor in surgically resected non-small cell lung cancer (16) . Furthermore, the activation of the MET-HGF signaling pathway has been described as one of the most critical events responsible for acquired anti-EGFR therapy resistance, and patients with increased MET gene copy numbers showed poor prognosis and resistance to EGFR tyrosine kinase inhibitors (TKI) (15, 16, 23) .
Some data indicate that about 20% of patients with acquired resistance to EGFR inhibition therapy and about 3% of treatment-naïve patients harbor MET amplification (24) . In preclinical models, lung cancer cell lines with MET amplification were shown to be dependent on MET signaling for growth and survival (25). As a result, many new MET inhibition compounds (including antibody inhibition, small molecule inhibitors and others) have entered clinical trials (9). However, to date the frequency of MET amplification in NSCLC remains controversial and it ranges from 3% to 10%, depending on the detection technique, cut-off criteria and selection of samples (15) (16) (17) (18) 26) . The aim of this study was to evaluate the prevalence of increased MET gene copy numbers in treatment-naïve non-small cell lung cancer patients via fluorescence in situ hybridization technique (FISH), to compare the findings to existing criteria for amplification as well as to potentially define clear cut-off criteria for subgroups of 
MATERIALS AND METHODS

Patients
The study was carried out with a total of 693 non-small cell lung cancer tumor samples with sufficient material for molecular diagnostics. 277 (40%) female patients and 416 male patients (60%) were included into the study with a mean age of 65.8 years (range 30-92 years). About two third of the samples consisted of biopsy specimens, the remaining cases were surgical resection samples. Unselected consecutive lung cancer patients who did not undergo prior non-surgical treatment were screened for MET amplification as part of the routine molecular diagnostics program (27) of the Network Genomic Medicine Cologne (NGM) between January 2011 and July 2013. The study was conducted in concordance with the local ethical guidelines and was reviewed by the institutional ethics committee. According to these data a total of four subgroups was defined: 1) wild-type adenocarcinomas (n=212, 30%), 2) KRAS-mutated adenocarcinomas (n=171, 25%), 3) EGFR-mutated carcinomas (n=138, 20%, including the two squamous cell carcinomas) and 4) squamous cell carcinomas (SCC: n=172, 25%).
Samples and subgroups
As already mentioned, we included unselected consecutive patients from our screening program. The given frequencies of the four groups, however, do not reflect the prevalence of these genetic findings in our entire screening cohort, since the selection of the patients was based on their molecular characteristics to adjust the frequencies of patients in the four groups. The same range (from 20% to 30%) was important for further statistical analysis. Despite the fact that the analyzed cohort was numerically adjusted to the same size of the included molecular subgroups, the entire cohort consists of unselected representative cases which were consecutively included (solely based on the four molecular subtypes which were collected prospectively in parallel). The subgroups are, therefore, representative and suitable for the evaluation of prevalence and the comparison between subgroups.
No cytology specimens were included. All tumor tissues were fixed in buffered formalin and embedded in paraffin blocks. Mutational analyses for EGFR and KRAS were carried out as previously described (28).
All primary diagnoses were reviewed by two experienced pathologists, according to current recommendations and tumor diagnoses were made in accordance to the current WHO classification system (29).
FISH assay
Fluorescence in situ hybridization was carried out as previously described (30, 31).
Briefly, three to four µm tissue sections were hybridized overnight with the ZytoLight SPEC MET/CEN7 Dual Color Probe (ZytoVision, Bremerhaven, Germany). Normal 
RESULTS
Detection of MET amplification by FISH
We obtained valid and easily evaluable FISH data for all 693 samples. Based on our findings in this representative cohort of pulmonary adeno-and squamous cell carcinomas we have noticed, that nearly two thirds of these tumors do not harbor any copy number gains of the MET gene. Thus, the majority of non-small cell lung cancers is disomic for chromosome 7 with a regular number of MET gene copies, 
restricted to the group of high-level cases and occurred only rarely in all other subgroups.
Distribution of amplification patterns
A total of 227 tumors (33%) showed criteria for any type of MET copy number gains Of all high-level amplified cases (n=22), 18 tumors showed an average number of MET signals ≥ 6 (mean: 4.5), 11 cases showed a MET/CEN7 ratio ≥ 2 (mean 1.5) and 11 of these cases exhibited ≥10% of tumor cells containing ≥15 MET signals or large clusters. Only five cases fulfilled all three criteria (Table 1) .
Correlation between MET amplification and protein expression
In order to evaluate whether our FISH evaluation score is related to and can be (15, 16, 18, 36) . Furthermore, some of these mechanisms may be related to each other. To date, two major issues are still unsatisfactorily addressed: i) which type of MET activation is relevant for which tumor entity and its initiation and propagation, and ii) in terms of biomarkers, which type of activation is predictive for which anti-MET compound.
In this study, we aimed to investigate MET amplification as one relevant mechanism of MET activation in non-small cell lung cancer. By analyzing a large cohort of squamous cell carcinomas and adenocarcinomas, to the best of our knowledge, we provide the currently most comprehensive data set on the prevalence of MET amplifications in therapy-naïve non-small cell lung cancer. Secondly, we are able to define amplification patterns of the MET gene and thirdly, we correlate our findings with common genetically defined subgroups of pulmonary carcinomas. Our findings may be useful in the context of screening programs for patients in upcoming clinical trials with c-MET inhibitors. Furthermore, they may also have impact on the future application of EGFR TKI therapy administration since our data provide evidence that MET amplification occurs also in EGFR mutated carcinomas prior to TKI treatment and hence may represent a mechanism of primary resistance to TKIs in these tumors. One major finding of our study is the fact that MET amplification can occur in both adenocarcinomas and squamous cell carcinomas of the lung and that MET amplifications appear even in the background of EGFR and KRAS mutations. Thus MET amplification does not fulfill the criteria of a genetically epistatic oncogenic driver lesion at least in these cases (37) . However, here we show unambiguously that MET amplification is not a mutually exclusive event to KRAS and/or EGFR mutation in adenocarcinomas. Our data reveal that both, high level amplification as 
In a recent report by the TCGA network (38) the frequency of MET amplifications was 2.2% which is basically in the range of our findings. Data from this particular publication, however, suggest that high level MET amplification is mutually exclusive with EGFR and KRAS mutations since MET amplification could not be detected in these molecular subgroups. This finding is in contrast to our aforementioned observation. One explanation for this discrepancy might be the number of analyzed samples. The TCGA cohort consisted of 230 pulmonary adenocarcinomas among them 32% KRAS (n=75) and 11% EGFR (n=26) mutants and a total of six MET amplified cases. On the other hand 171 KRAS and 138 EGFR mutated cases were included in our study, and we could detect a total of 22 samples with high level MET amplification. We found that EGFR/MET and KRAS/MET co-alterations are rare with 0.6% (3 out of 519 cases) and 0.4% (2/519) of all adenocarcinomas, respectively. Therefore, this phenomenon might not be perceptible in smaller cohorts. As mentioned before we are, however, convinced that co-alterations of MET and canonical oncogenic drivers might have direct clinical implications given the high incidence of lung cancer.
In summary, we here show that two thirds of non-small cell lung cancers do not reveal any changes in MET gene copy numbers whereas 3% of these tumors harbor high level amplification. Both of these categories can be considered as certain, to some extent independently from classification and scoring systems (see below).
Interestingly, nearly 30% of pulmonary non-small cell carcinomas in our study showed a moderate increase in MET gene copy numbers. Since this cohort was more heterogeneous and showed larger variations in gene copy numbers and MET/CEN7 ratio than negative or high level amplified cases, we defined the groups 
investigated non-small cell lung cancers .To date, it is unclear whether patients with these tumors will also benefit from anti-MET treatment.
Our aim was to propose an easily applicable MET amplification classification system, which might serve as a reliable basis and as a potential biomarker for consecutive studies of MET inhibitors. The defined thresholds are suggested on the basis from the experiences in our large cohort of nearly 700 consecutive lung cancer cases and previous attempts (15, 18, 32, 33) 
